加速θ爆发刺激治疗难治性抑郁:一项随机临床试验
在巴西圣保罗单中心开展的三盲假对照随机临床试验纳入100例难治性抑郁患者,比较加速θ爆发刺激(aTBS)与假刺激的疗效与安全性。第5周汉密尔顿抑郁量表17项(HDRS-17)评分较基线平均下降:假刺激组5.57(95%CI 3.99-7.16),活性组9.68(95%CI 8.11-11.25),效应量Cohen d为0.65(95%CI 0.29-1.00;P<.001)。活性组应答率和缓解率更高,两组耐受性良好,但活性组头皮疼痛更常见(17.4% vs 4.4%)。
要点
- aTBS组HDRS-17评分平均下降9.68,假刺激组下降5.57,效应量Cohen d为0.65(P<.001)。
- aTBS组应答率和缓解率均高于假刺激组。
- 活性组头皮疼痛发生率17.4%,假刺激组4.4%,两组总体耐受性良好。
核心结论
- 采用每日仅3次iTBS会话且无需神经导航的实用型aTBS方案对难治性抑郁安全有效。
研究设计与样本
- 三盲、假对照随机临床试验,在巴西圣保罗单中心开展,时间为2022年7月至2024年6月,随后设开放标签阶段。
- 纳入18至65岁、诊断为重度抑郁、当前为难治性抑郁发作且HDRS-17评分≥17分的患者;排除其他精神障碍(焦虑除外)、神经系统疾病及TBS禁忌者。
- 共筛查431名志愿者,纳入并随机100例;平均(SD)年龄41.7(8.8)岁,84例(84%)为女性;89例完成研究。
- 干预为15个工作日内共45次活性或假刺激会话,每日3次iTBS(每次1200脉冲),间隔30分钟,采用颅骨测量法定位左侧背外侧前额叶皮层。
主要发现
- 在意向性治疗分析中,HDRS-17评分从基线至研究终点平均变化:假刺激组5.57(95%CI 3.99-7.16),活性组9.68(95%CI 8.11-11.25),分别对应31.87%和54.7%的评分下降。
- 效应量为中等至较大(Cohen d=0.65;95%CI 0.29-1.00;P<.001)。
- 活性组应答率和缓解率均高于假刺激组。
- 两组干预均耐受良好,但活性组头皮疼痛比假刺激组更常见(17.4% vs 4.4%)。
- 开放标签阶段约75%的患者接受了额外会话。
关键数值与推荐
- 主要结局为第5周HDRS-17评分变化。
- 应答定义为HDRS-17评分改善≥50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intermittent theta-burst stimulation (iTBS) is an established treatment for treatment-resistant depression (TRD). Sessions conducted more than once daily (ie, accelerated TBS [aTBS]) may enhance antidepressant effects. However, evidence is limited to small trials, and protocols are time-consuming and can require neuroimaging-based targeting. OBJECTIVE: To evaluate the efficacy and safety of a pragmatic aTBS protocol for TRD. DESIGN, SETTING, AND PARTICIPANTS: This triple-blinded, sham-controlled randomized clinical trial was conducted at a single center in São Paulo, Brazil, from July 2022 to June 2024, with a subsequent open-label phase. Patients aged 18 to 65 years with major depression, experiencing a TRD episode, and with a Hamilton Depression Rating Scale, 17-item (HDRS-17) score of 17 or higher were eligible for inclusion. Exclusion criteria were other psychiatric disorders (except anxiety), neurological conditions, and TBS contraindications. INTERVENTIONS: Participants received 45 active or sham stimulation sessions over 15 weekdays, with 3 iTBS sessions (1200 pulses each) per day, spaced 30 minutes apart and targeting the left dorsolateral prefrontal cortex using a craniometric approach. In the open-label phase, additional aTBS sessions were offered to achieve a response (≥50% HDRS-17 score improvement) if needed. MAIN OUTCOMES AND MEASURES: The primary outcome was change in HDRS-17 score at week 5. RESULTS: Of 431 volunteers screened, 100 participants were enrolled and randomized to either sham or active aTBS. Mean (SD) participant age was 41.7 (8.8) years, and 84 participants (84%) were female. A total of 89 patients completed the study. In the intention-to-treat analysis, the mean change in HDRS-17 scores from baseline to the study end point was 5.57 (95% CI, 3.99-7.16) in the sham group and 9.68 (95% CI, 8.11-11.25) in the active group, corresponding to 31.87% and 54.7% score reductions, respectively, and a medium-to-large effect size (Cohen d, 0.65; 95% CI, 0.29-1.00; P < .001). Response and remission rates were also higher in the active group. Both interventions were well tolerated, but scalp pain was more frequent in the active group than the sham group (17.4% vs 4.4%). During the open-label phase, approximately 75% of patients received additional sessions. CONCLUSIONS AND RELEVANCE: In this triple-blinded, sham-controlled randomized clinical trial, a pragmatic aTBS protocol using only 3 iTBS sessions per day and a nonexpensive, non-neuronavigated approach was found to be safe and effective for TRD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05388539.
引用
- Ramos MRF, Goerigk S, Aparecida da Silva V, et al. Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40042840. doi:10.1001/jamapsychiatry.2025.0013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。